U.S. License Holder:
Date of License:
OCREVUS (ocrelizumab) is a CD20-directed cytolytic antibody indicated for the treatment of:
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults;
Primary progressive MS, in adults.